Suchergebnisse - "*Ritonavir"

PubPharm (8)

1

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

enthalten in: BMC infectious diseases | 2019

von Laker, E. | Nabaggala, M. | Kaimal, A. | +6

2

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression : a retrospective study from the clinical practice

enthalten in: BMC infectious diseases | 2019

von Borghetti, A. | Lombardi, F. | Gagliardini, R. | +10

3

A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi

enthalten in: BMC infectious diseases | 2017

von Ongubo, D. | Lim, R. | Tweya, H. | +9

4

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

enthalten in: BMC infectious diseases | 2017

von Antoniou, T. | Szadkowski, L. | Walmsley, S. | +79

5

Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort

enthalten in: BMC infectious diseases | 2017

von Postorino, M. | Prosperi, M. | Focà, E. | +11

6

Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection : an observational study

enthalten in: BMC infectious diseases | 2014

von Hattab, S. | Guihot, A. | Guiguet, M. | +7

7

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV : experience in a pediatric population

enthalten in: BMC infectious diseases | 2012

von Rusconi, S. | Giacomet, V. | Mameli, C. | +5

8

Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure

enthalten in: BMC infectious diseases | 2009

von Hsieh, S. | Chang, S. | Hung, C. | +3

1
[1]